Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,337,586
  • Shares Outstanding, K 52,869
  • Annual Sales, $ 95,390 K
  • Annual Income, $ -368,010 K
  • 60-Month Beta 2.11
  • Price/Sales 14.57
  • Price/Cash Flow N/A
  • Price/Book 9.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -1.80
  • Number of Estimates 5
  • High Estimate -1.68
  • Low Estimate -1.89
  • Prior Year -1.54
  • Growth Rate Est. (year over year) -16.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.54 +10.15%
on 02/26/19
32.05 -19.10%
on 02/28/19
+1.75 (+7.24%)
since 02/21/19
3-Month
16.55 +56.68%
on 12/24/18
32.05 -19.10%
on 02/28/19
+8.82 (+51.55%)
since 12/21/18
52-Week
11.50 +125.48%
on 10/31/18
65.24 -60.25%
on 04/11/18
-32.01 (-55.25%)
since 03/21/18

Most Recent Stories

More News
Clovis Oncology Announces Presentations at 2019 AACR Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six abstracts highlighting progress in the Rubraca clinical development and lucitanib preclinical research programs will be presented...

CLVS : 25.96 (+2.61%)
Clovis Oncology to Highlight Rubraca(R) (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress

--Maintenance treatment with Rubraca improved median progression-free survival (PFS) and reduced the risk of progression vs placebo regardless of age subgroup

CLVS : 25.96 (+2.61%)
Shares of CLVS Up 17.8% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Clovis Oncology (NASDAQ:CLVS) on January 8th, 2019 at $23.25. In approximately 2 months, Clovis Oncology has returned 17.81% as of today's recent price of $27.39.

CLVS : 25.96 (+2.61%)
After Yesterday's Decline of 2.88%, Clovis Oncology Offers Investors Better Value

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $26.22 to a high of $26.68. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $26.44...

CLVS : 25.96 (+2.61%)
SmarTrend Watching for Potential Rebound in Shares of Clovis Oncology After 2.96% Loss

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $28.16 to a high of $28.88. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $28.93...

CLVS : 25.96 (+2.61%)
New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clovis Oncology, Inc. (NASDAQ:CLVS),...

WELL : 77.49 (+2.64%)
CLVS : 25.96 (+2.61%)
ULTI : 331.34 (+0.04%)
XNCR : 33.14 (+2.54%)
NLSN : 27.33 (+1.56%)
VNET : 8.52 (-0.70%)
Clovis Oncology Announces Availability of Rubraca(R) (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca(R) (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with platinum-sensitive...

CLVS : 25.96 (+2.61%)
Clovis Oncology Shares Up 26.8% Since SmarTrend's Buy Recommendation (CLVS)

SmarTrend identified an Uptrend for Clovis Oncology (NASDAQ:CLVS) on January 8th, 2019 at $23.25. In approximately 2 months, Clovis Oncology has returned 26.80% as of today's recent price of $29.48.

CLVS : 25.96 (+2.61%)
Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover

Clovis' (CLVS) top and bottom line miss estimates in the fourth quarter. However, Rubraca sales recover during the quarter.

AZN : 43.23 (+0.49%)
CLVS : 25.96 (+2.61%)
GSK : 41.39 (+1.42%)
BMY : 49.00 (-0.39%)
AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study

AstraZeneca (AZN) and Merck's Lynparza significantly delays disease progression in a late-stage study (POLO) evaluating it as first-line maintenance treatment in pancreatic cancer.

AZN : 43.23 (+0.49%)
MRK : 82.79 (+0.87%)
CLVS : 25.96 (+2.61%)
GSK : 41.39 (+1.42%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Trade CLVS with:

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

2nd Resistance Point 26.81
1st Resistance Point 26.05
Last Price 25.96
1st Support Level 24.74
2nd Support Level 24.19

See More

52-Week High 65.24
Fibonacci 61.8% 44.71
Fibonacci 50% 38.37
Fibonacci 38.2% 32.03
Last Price 25.96
52-Week Low 11.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar